Disclaimer: I'm a novice at all of this, i.e., public stock investment and pharma. However, it seems to me that the most glaring need CYDY has right now is qualifying data as proof of concept. Dr. J seems eminently qualified in that regard and a testimony bearing believer in Leronlimab's extraordinary medical promise. If Dr. J can do what he appears to be highly qualified to do and produce significant qualifying data I have little doubt he will happily step down as CEO and it should be rather easy for CYDY to attract a highly qualified business CEO to guide the company into significant profitability. Until we have significant data we have shit. Starting anew on someone to lead us to qualifying data at this point seems highly disruptive to me. My cheap advice is to ride it out or sell. All the noise from those who think they know better, when complaining about not being informed, seems rather silly to me. But hey, it's still a free country...at least what remains of one...so enjoy your commentary as you wish. Just my opinion.